Expert Discusses Biggest Updates in NSCLC Treatment


“I think the biggest [change] that we’ve seen is the addition of adjuvant or consolidated chemotherapy following the completion of concurrent chemotherapy and radiation. We have seen the 4-year overall survival data now and the 5-year update from the PACIFIC study in the adjuvant setting, obviously confirming the initial signal that patients who have initiation of immunotherapy early carry a significant risk reduction for progression and overall survival…”

For this episode of “The Vitals,” we spoke with Martin Dietrich, MD, PhD, an assistant professor of internal medicine at the University of Central Florida, a fellow of the American College of Physicians, and a medical oncologist at Florida Cancer Specialists & Research Institute. Dietrich highlighted some recent advances and ongoing research in stage III non–small cell lung cancer (NSCLC) and discussed some of the ways immunotherapy and targeted therapy has evolved in recent years.

Related Videos
Ahulwalia on Targeting the Blood Brain Barrier With Novel Immunotherapies and Precision Oncology
Beth Sandy on Incorporating Amivantamab and Mobocertinib into Clinical Practice for Patients With EGFR Exon 20 Insertion NSCLC
Experts on lung cancer
Experts on lung cancer
Experts on lung cancer
Experts on lung cancer
Stethoscope as a heart
Related Content
© 2024 MJH Life Sciences

All rights reserved.